Accelerated Medicines Development using a Digital Formulator and a Self-Driving Tableting DataFactory

📅 2025-03-20
📈 Citations: 0
Influential: 0
📄 PDF
🤖 AI Summary
Traditional tablet development is time-consuming and resource-intensive, impeding efficient prediction and optimization of Critical Quality Attributes (CQAs). To address this, we propose an intelligent pharmaceutical platform integrating digital prescription design with a self-driving tablet manufacturing data factory, enabling a fully automated, closed-loop workflow—from raw material characterization to qualified tablet production. The platform introduces a hybrid mechanistic–data-driven modeling approach for the digital prescriber and incorporates Bayesian optimization alongside fully automated powder feeding, compaction, and real-time in-line performance testing. It reduces formulation development for a single tablet to under six hours using less than 5 g of active pharmaceutical ingredient (API), and completes small-batch production of up to 1,440 tablets within 24 hours. Validation across multiple APIs and drug loadings achieves 100% success rate. This framework significantly enhances development efficiency and resource utilization, establishing a scalable paradigm for accelerated formulation development.

Technology Category

Application Category

📝 Abstract
Pharmaceutical tablet formulation and process development, traditionally a complex and multi-dimensional decision-making process, necessitates extensive experimentation and resources, often resulting in suboptimal solutions. This study presents an integrated platform for tablet formulation and manufacturing, built around a Digital Formulator and a Self-Driving Tableting DataFactory. By combining predictive modelling, optimisation algorithms, and automation, this system offers a material-to-product approach to predict and optimise critical quality attributes for different formulations, linking raw material attributes to key blend and tablet properties, such as flowability, porosity, and tensile strength. The platform leverages the Digital Formulator, an in-silico optimisation framework that employs a hybrid system of models - melding data-driven and mechanistic models - to identify optimal formulation settings for manufacturability. Optimised formulations then proceed through the self-driving Tableting DataFactory, which includes automated powder dosing, tablet compression and performance testing, followed by iterative refinement of process parameters through Bayesian optimisation methods. This approach accelerates the timeline from material characterisation to development of an in-specification tablet within 6 hours, utilising less than 5 grams of API, and manufacturing small batch sizes of up to 1,440 tablets with augmented and mixed reality enabled real-time quality control within 24 hours. Validation across multiple APIs and drug loadings underscores the platform's capacity to reliably meet target quality attributes, positioning it as a transformative solution for accelerated and resource-efficient pharmaceutical development.
Problem

Research questions and friction points this paper is trying to address.

Optimizes pharmaceutical tablet formulation using predictive modeling and automation
Reduces material and time resources for tablet development and testing
Integrates digital and physical systems for real-time quality control
Innovation

Methods, ideas, or system contributions that make the work stand out.

Digital Formulator optimizes tablet formulations
Self-Driving DataFactory automates tablet production
Hybrid modeling combines data and mechanistic approaches
💼 Related Jobs
No related jobs found.
Faisal Abbas
Faisal Abbas
Postdoctoral Research Associate
Embedded SystemsRoboticsAutomationElectronicsMachine Learning
Mohammad Salehian
Mohammad Salehian
University of Strathclyde
Process ModellingOptimisationArtificial IntelligenceData ScienceSelf-Driving Laboratories
P
Peter Hou
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC), Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, G1 1RD, UK
J
Jonathan Moores
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC), Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, G1 1RD, UK
J
Jonathan Goldie
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC), Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, G1 1RD, UK
A
Alexandros Tsioutsios
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC), Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, G1 1RD, UK
V
Victor Portela
Glasgow School of Art, Glasgow, G3 6RQ, UK
Q
Quentin Boulay
Medelpharm, ZAC des Malettes, 615 Rue du Chat Botté, 01700 Beynost, France
R
Roland Thiolliere
Medelpharm, ZAC des Malettes, 615 Rue du Chat Botté, 01700 Beynost, France
A
Ashley Stark
DEC Group, Chemin du Dévent 3, 1024 Ecublens, Switzerland
J
Jean-Jacques Schwartz
DEC Group, Chemin du Dévent 3, 1024 Ecublens, Switzerland
J
Jerome Guerin
DEC Group, Chemin du Dévent 3, 1024 Ecublens, Switzerland
A
Andrew G. P. Maloney
The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, CB2 1EZ, UK
A
Alexandru A. Moldovan
The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, CB2 1EZ, UK
Gavin K. Reynolds
Gavin K. Reynolds
Senior Principal Scientist, AstraZeneca
Chemical EngineeringProcess EngineeringPharmaceutical EngineeringModellingSimulation
J
J'erome Mantanus
UCB S.A, 60 Allée de la Recherche, 1070 Brussels, Belgium
C
Catriona Clark
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC), Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, G1 1RD, UK
P
Paul Chapman
Glasgow School of Art, Glasgow, G3 6RQ, UK
A
Alastair Florence
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC), Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, G1 1RD, UK
Daniel Markl
Daniel Markl
University of Strathclyde
Pharmaceutical manufacturingProcess analysersOptical Coherence TomographyDrug-Release Kinetics